Our CLINICAL TRIAL is now Recruiting Type 2 Diabetes Patients
Concenter Biopharma, together with the SHEBA Medical Center in Israel recently began recruiting patients for the clinical trial using the company's Zygosid-50 Drug. The Trial is examining the Safety and Efficacy of Zygosid-50 Administered by Sub-Cutaneous Injection for Glycemic Control of Patients with Type 2 Diabetes Mellitus.
Inclusion criteria in the trial include:
1.Male or female subjects with T2DM.
2.Age: 30 - 80 years.
3.10.5%>HbA1c >7.5%, and Hb>14 g/dl for men, and Hb>12 g/dl for women.
4.Stable diabetes treatment for the last 3 months.
5.Treatment with any anti-diabetic drugs except insulin.
6.BMI of 27 to 35 If you think you are interested in hearing more abbot the trial please contact our Chief Medical Officer - Prof. Amir Elami: amir@concenterbiopharma.com
Information (Hebrew) from the Israeli Ministry of Health website: https://my.health.gov.il/CliniTrials/Pages/MOH_2021-04-06_009876.aspx
